139 related articles for article (PubMed ID: 37487844)
1. Post-approval quality-related regulatory actions for biopharmaceuticals approved in the European Union and the United States between 1995 and 2019.
Alsamil AM; Gardarsdottir H; Leufkens HG; Egberts TC; Giezen TJ
Drug Discov Today; 2023 Oct; 28(10):103725. PubMed ID: 37487844
[TBL] [Abstract][Full Text] [Related]
2. Safety-related regulatory actions for biologicals approved in the United States and the European Union.
Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Schellekens H; Leufkens HG; Egberts AC
JAMA; 2008 Oct; 300(16):1887-96. PubMed ID: 18940975
[TBL] [Abstract][Full Text] [Related]
3. A cohort study exploring determinants of safety-related regulatory actions for biopharmaceuticals.
Ebbers HC; Mantel-Teeuwisse AK; Moors EH; Sayed Tabatabaei FA; Schellekens H; Leufkens HG
Drug Saf; 2012 May; 35(5):417-27. PubMed ID: 22506566
[TBL] [Abstract][Full Text] [Related]
4. Biopharmaceuticals approved in the EU 1995-1999: a European Union-United States comparison.
Reichert JM; Healy EM
Eur J Pharm Biopharm; 2001 Jan; 51(1):1-7. PubMed ID: 11154897
[TBL] [Abstract][Full Text] [Related]
5. Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study.
Heemstra HE; Giezen TJ; Mantel-Teeuwisse AK; de Vrueh RL; Leufkens HG
Drug Saf; 2010 Feb; 33(2):127-37. PubMed ID: 20082539
[TBL] [Abstract][Full Text] [Related]
6. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
[TBL] [Abstract][Full Text] [Related]
7. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.
Mol PG; Straus SM; Piening S; de Vries JT; de Graeff PA; Haaijer-Ruskamp FM
Drug Saf; 2010 Jun; 33(6):463-74. PubMed ID: 20486729
[TBL] [Abstract][Full Text] [Related]
8. Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries.
Kim J; Park J; Song SY; Kim E
Regen Ther; 2022 Jun; 20():126-137. PubMed ID: 35582708
[TBL] [Abstract][Full Text] [Related]
9. Differences between post-authorization adverse drug reactions of biopharmaceuticals and small molecules.
Ebbers HC; Al-Temimi E; Moors EH; Mantel-Teeuwisse AK; Schellekens H; Leufkens HG
BioDrugs; 2013 Apr; 27(2):167-74. PubMed ID: 23400874
[TBL] [Abstract][Full Text] [Related]
10. Biosimilar therapeutics-what do we need to consider?
Schellekens H
NDT Plus; 2009 Jan; 2(Suppl_1):i27-i36. PubMed ID: 19461855
[TBL] [Abstract][Full Text] [Related]
11. A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU.
da Costa Gonçalves F; Demirci E; Zwiers A
Clin Transl Sci; 2022 Aug; 15(8):1959-1967. PubMed ID: 35561071
[TBL] [Abstract][Full Text] [Related]
12. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.
Tsuji K; Tsutani K
Eur J Pharm Biopharm; 2008 Mar; 68(3):496-502. PubMed ID: 17884403
[TBL] [Abstract][Full Text] [Related]
13. Timing of Pediatric Drug Approval and Clinical Evidence Submitted to Regulatory Authorities: International Comparison Among Japan, the United States, and the European Union.
Hirota S; Yamaguchi T
Clin Pharmacol Ther; 2020 Nov; 108(5):985-994. PubMed ID: 31869436
[TBL] [Abstract][Full Text] [Related]
14. Medical Device Regulation: A Comparison of the United States and the European Union.
Maak TG; Wylie JD
J Am Acad Orthop Surg; 2016 Aug; 24(8):537-43. PubMed ID: 27195383
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars: policy, clinical, and regulatory considerations.
Gottlieb S
Am J Health Syst Pharm; 2008 Jul; 65(14 Suppl 6):S2-8. PubMed ID: 18591712
[TBL] [Abstract][Full Text] [Related]
16. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
[TBL] [Abstract][Full Text] [Related]
17. Maintaining consistent quality and clinical performance of biopharmaceuticals.
Lamanna WC; Holzmann J; Cohen HP; Guo X; Schweigler M; Stangler T; Seidl A; Schiestl M
Expert Opin Biol Ther; 2018 Apr; 18(4):369-379. PubMed ID: 29285958
[TBL] [Abstract][Full Text] [Related]
18. Relevant issues to biossimilars licensing.
Peres BS; Padilha G; Quental C
Rev Bras Epidemiol; 2012 Dec; 15(4):748-60. PubMed ID: 23515771
[TBL] [Abstract][Full Text] [Related]
19. Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States.
Bhasale AL; Sarpatwari A; De Bruin ML; Lexchin J; Lopert R; Bahri P; Mintzes BJ
Clin Pharmacol Ther; 2021 Jun; 109(6):1424-1442. PubMed ID: 32767557
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceutical biotechnology products approved within the European Union.
Walsh G
Eur J Pharm Biopharm; 2003 Jan; 55(1):3-10. PubMed ID: 12551698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
